{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05664516",
            "orgStudyIdInfo": {
                "id": "2022P002727"
            },
            "organization": {
                "fullName": "Massachusetts General Hospital",
                "class": "OTHER"
            },
            "briefTitle": "A Study of the Effects of Oxytocin in Adults With Obesity and Binge-eating Disorder",
            "officialTitle": "A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Intranasal Oxytocin in Adults With Obesity and Binge- Eating Disorder",
            "acronym": "STROBE",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-study-of-the-effects-of-oxytocin-in-adults-with-obesity-and-binge-eating-disorder"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-03-07",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-04",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-04",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-12-16",
            "studyFirstSubmitQcDate": "2022-12-16",
            "studyFirstPostDateStruct": {
                "date": "2022-12-23",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-03-22",
            "lastUpdatePostDateStruct": {
                "date": "2023-03-24",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Elizabeth Austen Lawson",
                "investigatorTitle": "Director, Interdisciplinary Oxytocin Research Program",
                "investigatorAffiliation": "Massachusetts General Hospital"
            },
            "leadSponsor": {
                "name": "Massachusetts General Hospital",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study evaluates the impact of intranasal oxytocin vs placebo in patients with obesity and binge eating disorder with obesity. We hypothesize that 8 weeks of intranasal oxytocin vs placebo will improve clinical outcomes \\[weight loss, reduction in bingeing frequency\\], and have a satisfactory safety and tolerability profile. We will also explore the predictive value of changes in homeostatic appetite, reward sensitivity, and impulse control, the identified underlying mediators, as assessed 4 weeks into the intervention, for treatment success after 8 weeks of the intervention",
            "detailedDescription": "Study staff will screen patients for eligibility as per eligibility criteria. At least 60 eligible patients will be randomized 1:1 (active oxytocin: placebo) by an unblinded pharmacist. All other study staff and test subjects will be blinded. Study subject medical histories, physical exams, anthropometric measurements, labs, EKG's, and eating habits will be monitored over 8 weeks. Subjects will be evaluated at the following intervals: Baseline, week 2, week 4, and week 8."
        },
        "conditionsModule": {
            "conditions": [
                "Binge-eating Disorder"
            ],
            "keywords": [
                "Obesity",
                "Weight Loss",
                "Binge",
                "Binge-eating disorder",
                "Oxytocin",
                "Overeating"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "maskingDescription": "Study staff and patients are blinded. The pharmacist is unblinded.",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 60,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Placebo Arm",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Solution without oxytocin",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                },
                {
                    "label": "TNX-1900",
                    "type": "EXPERIMENTAL",
                    "description": "Solution with oxytocin",
                    "interventionNames": [
                        "Drug: TNX-1900 (Tonix Pharmaceuticals)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "TNX-1900 (Tonix Pharmaceuticals)",
                    "description": "oxytocin nasal spray",
                    "armGroupLabels": [
                        "TNX-1900"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Nasal solution without oxytocin",
                    "armGroupLabels": [
                        "Placebo Arm"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "weight (kg)",
                    "description": "Change from baseline in weight",
                    "timeFrame": "8 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Binge Frequency",
                    "description": "Change from baseline in binge frequency as assessed by the Eating Disorder Examination clinical interview",
                    "timeFrame": "8 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Males and females, 18-45 years old\n* BMI 30-50 kg/m2\n* BED as assessed by Structured Clinical Interview for DSM-5 Disorders (SCID-5-RV)\n\nExclusion Criteria:\n\n* Substance use disorder active within the last 6 months, or clinical suspicion of ongoing substance use disorder at the discretion of the study clinician at the time of screening based on history and/or laboratory results\n* Medication changes within 4 weeks of baseline visit\n* Use of prescription or over-the-counter drugs or dietary/herbal supplements for weight loss (e.g., lorcaserin, phentermine, topiramate, liraglutide). Metformin will be allowed if participants are on a stable dose with stable weight for at least 3 months\n* History of any of the following medical conditions: inflammatory bowel disease; bariatric surgery (except for those participants with a history of laparoscopic adjustable gastric band surgery); epilepsy; untreated thyroid disease\n* History of known cardiovascular disease, including coronary artery disease, heart failure, reduced ejection fraction, hypertrophic cardiomyopathy, ventricular arrhythmias, or prolonged QT\n* Hematocrit \\>2% below normal\n* Hemoglobin A1c \\>8%\n* ALT or AST \\>2.5 times upper limit of normal\n* Glomerular filtration rate \\< 60 mL/min\n* Hyponatremia\n* Pregnancy or breastfeeding\n* Unwilling to use a medically acceptable form of contraception throughout the study period (female of child-bearing potential only)\n* History of psychosis or active suicidality as assessed by the SCID-5-RV\n* Weight change \\>5 kg within 3 months prior to randomization\n* Current smoking or tobacco use\n* Participation in any clinical study involving an investigational drug, device, or biologic within 1 month of randomization\n* Any significant illness, condition, or medication that the Investigator determines could interfere with study participation and impact data collection or patient safety",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "45 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Sarah Smith, NP",
                    "role": "CONTACT",
                    "phone": "617-726-9394",
                    "email": "SSMITH133@MGH.HARVARD.EDU"
                }
            ],
            "locations": [
                {
                    "facility": "Neuroendocrine Unit Research Center",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02114",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sara Smith, DNP, MSN",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009765",
                    "term": "Obesity"
                },
                {
                    "id": "D000002032",
                    "term": "Bulimia"
                },
                {
                    "id": "D000001068",
                    "term": "Feeding and Eating Disorders"
                },
                {
                    "id": "D000056912",
                    "term": "Binge-Eating Disorder"
                }
            ],
            "ancestors": [
                {
                    "id": "D000050177",
                    "term": "Overweight"
                },
                {
                    "id": "D000044343",
                    "term": "Overnutrition"
                },
                {
                    "id": "D000009748",
                    "term": "Nutrition Disorders"
                },
                {
                    "id": "D000001835",
                    "term": "Body Weight"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                },
                {
                    "id": "D000006963",
                    "term": "Hyperphagia"
                },
                {
                    "id": "D000012817",
                    "term": "Signs and Symptoms, Digestive"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5304",
                    "name": "Bulimia",
                    "asFound": "Binge Eating",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5114",
                    "name": "Body Weight",
                    "relevance": "LOW"
                },
                {
                    "id": "M28641",
                    "name": "Binge-Eating Disorder",
                    "asFound": "Binge Eating Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12701",
                    "name": "Obesity",
                    "asFound": "Obesity",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18102",
                    "name": "Weight Loss",
                    "relevance": "LOW"
                },
                {
                    "id": "M10014",
                    "name": "Hyperphagia",
                    "relevance": "LOW"
                },
                {
                    "id": "M26956",
                    "name": "Bulimia Nervosa",
                    "relevance": "LOW"
                },
                {
                    "id": "M4380",
                    "name": "Feeding and Eating Disorders",
                    "asFound": "Eating Disorders",
                    "relevance": "HIGH"
                },
                {
                    "id": "M26186",
                    "name": "Overweight",
                    "relevance": "LOW"
                },
                {
                    "id": "M25307",
                    "name": "Overnutrition",
                    "relevance": "LOW"
                },
                {
                    "id": "M12684",
                    "name": "Nutrition Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M15622",
                    "name": "Signs and Symptoms, Digestive",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                },
                {
                    "id": "M13041",
                    "name": "Oxytocin",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Repr",
                    "name": "Reproductive Control Agents"
                }
            ]
        }
    },
    "hasResults": false
}